Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Rhythm Biosciences Ltd. ( (AU:RHY) ) has provided an announcement.
Rhythm Biosciences has notified the ASX of a proposed issue of up to 625,000 ordinary fully paid shares under a placement or similar capital-raising mechanism, with the new securities expected to be issued on 2 February 2026. The move signals an intention to bolster the company’s capital base, which may support ongoing operations and development activities, and could modestly dilute existing shareholders while potentially strengthening Rhythm’s financial position ahead of future milestones.
The most recent analyst rating on (AU:RHY) stock is a Hold with a A$0.10 price target. To see the full list of analyst forecasts on Rhythm Biosciences Ltd. stock, see the AU:RHY Stock Forecast page.
More about Rhythm Biosciences Ltd.
Rhythm Biosciences Ltd is an ASX-listed biotechnology company focused on developing diagnostic technologies, with its ordinary fully paid shares trading under the ticker RHY.
Average Trading Volume: 451,121
Technical Sentiment Signal: Buy
Current Market Cap: A$28.65M
For an in-depth examination of RHY stock, go to TipRanks’ Overview page.